Press Releases September 2, 2026 08:30 AM

MannKind to Present at Upcoming Investor Conferences

MannKind Corporation to Present at Two Major Investor Conferences in September 2026

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
MNKD

MannKind Corporation announced that its management team will participate in the Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference in September 2026, delivering presentations via live audio webcasts. The company focuses on innovative biopharmaceutical treatments for cardiometabolic and orphan lung diseases.

MannKind to Present at Upcoming Investor Conferences
MNKD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • MannKind to engage investors with presentations at two prominent healthcare investment conferences in New York.
  • Focus remains on development and commercialization of treatments for diabetes, pulmonary hypertension, and complications from heart failure and chronic kidney disease.
  • The company highlights its expertise in drug-device combination therapies aimed at improving patient quality of life.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that members of the MannKind management team will present at the following upcoming investor conferences:

Cantor Global Healthcare Conference (New York, NY)
Fireside Chat, Thursday, September 10, 2026, at 11:30 a.m. ET

H.C. Wainwright 28th Annual Global Investment Conference (New York, NY)
Fireside Chat, Tuesday, September 15, 2026, at 9:30 a.m. ET

Links to the live audio webcasts of the presentations will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. A recorded version will also be available on the website for approximately 90 days following the conference.

About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.


Risks

  • Investor presentations may not lead to immediate changes in stock price or attract new investment, leading to neutral market reaction.
  • Biopharmaceutical developments carry inherent regulatory and clinical trial risks which can affect future products and financial performance.
  • Market competition and evolving healthcare regulations in the cardiometabolic and orphan diseases sectors could impact MannKind's growth prospects.

More from Press Releases

Orlando Magic and Gray Media Announce Full Season Broadcast Partnership Sep 2, 2026 Kyivstar to Release 3Q26 Earnings on November 6, 2026 Reschedules Capital Markets Day to November 17, 2026 Sep 2, 2026 Wolseley Canada Announces Andy Mallon as Chief Financial Officer Sep 2, 2026 Donna Karan New York Unveils Its Fall 2026 Campaign Featuring Kendall Jenner Sep 2, 2026 Virtuix to Showcase AI-Enabled Counter-Drone Training System to U.S. Army Leaders at Maneuver Warfighter Conference Sep 2, 2026